# Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

> **NCT06909201** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** HP 129Xe MRI

## Key facts

- **NCT ID:** NCT06909201
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909201, "Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06909201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*